Jazz Pharmaceuticals JAZZ Provision for losses on accounts receivable and inventory
Provision for losses on accounts receivable and inventory at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:ProvisionForLossesOnAccountsReceivableAndInventory.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory?
- Jazz Pharmaceuticals (JAZZ) reported provision for losses on accounts receivable and inventory of $14.2M in Q1 2026.
- How has Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory changed year-over-year?
- Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory increased by 167.9% year-over-year, from $5.3M to $14.2M.
- What is the long-term trend for Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory?
- Over 2 years (2021 to 2025), Jazz Pharmaceuticals's provision for losses on accounts receivable and inventory has grown at a -1.4% compound annual growth rate (CAGR), from $19.67M to $19.11M.
- What does provision for losses on accounts receivable and inventory mean?
- Accounting charge for expected losses on unpaid customer bills or unusable inventory.
- How do you interpret provision for losses on accounts receivable and inventory?
- An increase suggests deteriorating credit quality of customers or potential issues with product demand and inventory management.
- How does provision for losses on accounts receivable and inventory compare across companies?
- A standard risk-management metric across all industries to ensure balance sheet accuracy.